A 34-gene signature can predict the behavior of meningiomas more accurately than microscopic pathology, researchers reported in Nature Medicine. Meningiomas, the most common type of central nervous system tumor, generally are benign, but their behavior has been difficult to predict based on pathology. The study is a major step forward in managing meningiomas and could lead to more effective, personalized treatment.

Using a formal framework for a team debriefing after an emotionally challenging critical event can create a positive learning experience, initiate process improvements, and ultimately offer nurses and other healthcare professionals psychological support that reduces burnout and compassion fatigue, ONS members Molly Joyce, MSN, APRN, OCN^®, and Joanne Itano, RN, PhD, reported in an article published in the February 2024 issue of the Clinical Journal of Oncology Nursing.

On March 27, 2024, the U.S. Food and Drug Administration (FDA) announced that Amneal Pharmaceuticals, LLC, is voluntarily recalling four lots of vancomycin hydrochloride for oral solution, USP, 250 mg/5 ml, packaged in 80 ml, 150 ml, or 300 ml pack sizes, to the consumer level.

Lesbian, gay, and bisexual (LGB) adolescent and young adult (AYA) cancer survivors are at greater risk for chronic health conditions than LGB individuals without a cancer history and heterosexual AYA cancer survivors, researchers reported in a recent study. Published in Cancer, the study findings underscore the disparities in care that LGB AYA cancer survivors face and the need to address barriers and personalize survivorship care.

This ONS resource was produced for educational purposes only. Refer to the full elranatamab-bcmm (Elrexfio™) package insert for all details.

Since 1995, the U.S. Food and Drug Administration (FDA) has received submissions for more than 300 drugs and biological products with artificial intelligence (AI) components and more than 700 AI-enabled devices, Commissioner Robert M. Califf, MD, said in a March 2024 blog post.  

On March 22, 2024, the U.S. Food and Drug Administration (FDA) fully approved mirvetuximab soravtansine-gynx (Elahere^®) for adult patients with FR alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. Patients are selected for treatment based on an FDA-approved test. FDA gave mirvetuximab soravtansine-gynx accelerated approval for the indication in November 2022.

On March 21, 2024, the U.S. Food and Drug Administration (FDA) approved safety labeling changes regarding dihydropyrimidine dehydrogenase deficiency for fluorouracil injection products. The update was a collaboration between FDA’s Office of Generic Drugs and the Oncology Center of Excellence.

Senate Finance Committee Chair Ron Wyden (D-OR) and Ranking Member Mike Crapo (R-ID) today announced their commitment to working on bipartisan healthcare legislation to prevent and mitigate shortages of critical generic drugs used by patients and providers in the United States.

A gene found on many germline cancer testing panels, RecQ like helicase 4 (RECQL4) is located on chromosome 8. Although it was first described in 1998, its associated cancer risks and implications for treatment are still not well understood.